IgNova announced today that it has filed a patent application covering the use 
of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a 
biopharmaceutical R&D start up, researches technology based on specific egg 
immunoglobulins (IgY).   

The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus 
when it enters the mouth or nose and, therefore, inhibiting the infection 
process. IgNova's technology offers a safe, economical, and unlimited source of 
polyclonal antibodies to control SARS-CoV-2. 

The IgY antibody technology has a wide range of applications such as chewable 
tablets, sprays, or mouthwash, offering instant protection against SARS-CoV-2. 
Additional applications, such as IgY-coated air filters and masks, could 
potentially support medical professionals and other at-risk professions. With 
antigen and antibody production as well as specific applications included in 
the patent, IgNova envisions an exhaustive IgY technology response to 
COVID-19.  

"We are at the final research stage," says Michael Gerrits, IgNova Managing 
Director, "working closely with scientific institutions and potential strategic 
partners to bring the technology to market. We have started initial testing 
with the objective to allow our partners to introduce IgNova technology based 
products to market in Q4 2020."

IgNova's patent is based on proprietary IgY technology, a process that involves 
immunizing chickens against target pathogens, extracting antibodies from eggs. 
IgY technology was developed in the 1980s to help control dental caries. In 
Japan, the technology is widely used both in food and human health applications.

"Early research looks promising," says IgNova Managing Director Tonchy 
Ugrinovic. "With the right scientific and production partners, IgNova targets a 
mass-marketable solution in Q4 of this year 2020." 

About IgNova

Founded in 2013, IgNova is a biopharmaceutical R&D start up that drives IgY 
technology innovation in accordance with stringent quality management and 
design control standards. At production sites in the US, Japan, and Europe, 
cutting-edge health and safety solutions are developed in close collaboration 
with industry partners. 
 
Contact 
Pia Becker  
Tel: +49 4445 9868174   
Mobile: +49 151 10464268   
Email: contact@ignova.com

Source: IgNova GmbH